Engineering solutions to design CAR-T cells

Irene Uboldi, Praseet Poduval, Jai Prakash

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

Engineering T cells with chimeric antigen receptors (CAR) to create CAR-T cells has emerged as promising immunotherapy. CAR-T cell-based therapies have shown clinical success in treating hematological malignancies. On contrary, CAR-T cells therapy for solid tumors has still a limited success and considerable effort is required for an improvement in the efficacy. This chapter will describe the developments in CAR structure (CARs generations) over the years. It will mainly focus on state-of-the-art engineering solutions proposed to enhance the therapeutic efficacy of CAR-T cells and on gene delivery strategies used to create CAR-T cells. Finally, some critical aspects for the clinical development of CAR-T cells will be discussed.

Original languageEnglish
Title of host publicationEngineering Technologies and Clinical Translation
Subtitle of host publicationVolume 3 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy
PublisherElsevier
Chapter1
Pages1-31
Number of pages31
ISBN (Electronic)9780323909495
ISBN (Print)9780323909501
DOIs
Publication statusPublished - 1 Jan 2022

Keywords

  • Bioengineering
  • Cancer therapeutics
  • CAR-T cells
  • Chimeric antigen receptor
  • Drug delivery
  • Genetic engineering
  • Immuno-oncology
  • Immunotherapy

Fingerprint

Dive into the research topics of 'Engineering solutions to design CAR-T cells'. Together they form a unique fingerprint.

Cite this